Weill Cornell Medicine researchers found that restricting telehealth prescriptions for opioid use disorder could keep thousands from accessing buprenorphine, a medication that helps people recover from addiction. The study, published March 3 in JAMA Network Open, warns that requiring in-person visits—as had been proposed by the Drug Enforcement Agency (DEA)—may undo the progress made during the COVID-19 pandemic when telehealth increased access to this life-saving treatment. Previous studies show telehealth buprenorphine prescriptions improve treatment use and reduce overdose rates.
Before the pandemic, federal law required doctors to examine patients in person before prescribing controlled substances. This rule was suspended temporarily in March 2020, allowing doctors to prescribe buprenorphine through online telehealth visits, which made receiving treatment for opioid use disorders easier, especially for those in rural areas or without reliable transportation.